Neuronal and glial purinergic receptors functions in neuron development and brain disease by Wandosell, Francisco et al.
“fncel-07-00197” — 2013/10/25 — 11:25 — page 1 — #1
REVIEW ARTICLE
published: 28 October 2013
doi: 10.3389/fncel.2013.00197
Neuronal and glial purinergic receptors functions in neuron
development and brain disease
Ana del Puerto1,2 , FranciscoWandosell 2,3 and Juan José Garrido1,2*
1 Department of Molecular, Cellular and Developmental Neurobiology, Instituto Cajal, Consejo Superior de Investigaciones Cientíﬁcas, Madrid, Spain
2 Centro de Investigación Biomédica en Red de Enfermedades Neurodegenerativas, Madrid, Spain
3 Centro de Biología Molecular “Severo Ochoa”, Consejo Superior de Investigaciones Cientíﬁcas-Universidad Autónoma de Madrid, Madrid, Spain
Edited by:
Martin Stangel, Hannover Medical
School, Germany
Reviewed by:
Alexej Verkhratsky, University of
Manchester, UK
Illes Peter, University of Leipzig,
Germany
*Correspondence:
Juan José Garrido, Instituto Cajal,
Consejo Superior de Investigaciones
Cientíﬁcas, Avenida Doctor Arce 37,
Madrid 28002, Spain
e-mail: jjgarrido@cajal.csic.es
Brain development requires the interaction of complex signaling pathways, involving
different cell types and molecules. For a long time, most attention has focused on neurons
in a neuronocentric conceptualization of central nervous system development, these cells
fulﬁlling an intrinsic program that establishes the brain’s morphology and function. By
contrast, glia have mainly been studied as support cells, offering guidance or as the
cells that react to brain injury. However, new evidence is appearing that demonstrates
a more fundamental role of glial cells in the control of different aspects of neuronal
development and function, events in which the inﬂuence of neurons is at best weak.
Moreover, it is becoming clear that the function and organization of the nervous system
depends heavily on reciprocal neuron–glia interactions. During development, neurons
are often generated far from their ﬁnal destination and while intrinsic mechanisms are
responsible for neuronalmigration and growth, they need support and regulatory inﬂuences
from glial cells in order to migrate correctly. Similarly, the axons emitted by neurons
often have to reach faraway targets and in this sense, glia help deﬁne the way that
axons grow. Moreover, oligodendrocytes and Schwann cells ultimately envelop axons,
contributing to the generation of nodes of Ranvier. Finally, recent publications show
that astrocytes contribute to the modulation of synaptic transmission. In this sense,
purinergic receptors are expressed widely by glial cells and neurons, and recent evidence
points to multiple roles of purines and purinergic receptors in neuronal development and
function, from neurogenesis to axon growth and functional axonal maturation, as well as in
pathological conditions in the brain. This review will focus on the role of glial and neuronal
secreted purines, and on the purinergic receptors, fundamentally in the control of neuronal
development and function, as well as in diseases of the nervous system.
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INTRODUCTION
A plethora of different regulatory molecules are involved in the
crosstalk between neurons and glia during neuronal development.
In many cases, glial cells secrete molecules that are detected syn-
chronously, either by the neuron as a whole or speciﬁcally by the
axonal growth cone. Many studies have described the essential
role of neurotrophic factors and their tyrosine kinase receptors
(nerve growth factor (NGF), brain-derived neurotrophic factor
(BDNF), NT-3, FGFs, insulin-like growth factor 1 (IGF-I), etc.) in
axon growth and neuronal survival. Indeed, many of these factors
are produced by glial cells to modulate neuronal behavior dur-
ing development. These factors control the activity of PI3-kinase
(Alsina et al., 2012; Numakawa et al., 2012), which is essential for
axon development, elongation, and maintenance (Sanchez et al.,
2001; Shi et al., 2003), and indeed, the activity of this kinase can
be regulated through different membrane receptors and adhesion
molecules, including integrins.
The insulin/IGF-I system it has been studied widely in both
neuronal and non-neuronal cells, controlling processes such
as survival-apoptosis (Pap and Cooper, 1998). This survival
route is controlled by an insulin-IGF-I-receptor/PI3K/Akt path-
way. In addition, central and peripheral insulin-like peptides
(ILPs), including insulin, IGF-I, and IGF-II, can produce many
other distinct effects in the brain and in neurons (Llorens-
Martin et al., 2008; Fernandez and Torres-Aleman, 2012). For
instance, the PI3K/Akt pathway appears to regulate neuritogen-
esis/axonogenesis (Shi et al., 2003; Sosa et al., 2006) and in fact,
PI3K inhibition prevents axonal initiation in hippocampal neu-
rons (Shi et al., 2003), or it induces growth cone collapse and
neurite retraction (Sanchez et al., 2001), demonstrating the role of
PI3K activity in axonal elongation. GSK3 acts downstream PI3K
and it represents a second element controlling axonogenesis and
neuronal polarity, to the point that GSK3 inhibition (Shi et al.,
2004) or GSK3α/β suppression prevents neurons from polarizing
(Garrido et al., 2007).
G-protein-coupled receptors (GPCRs) also play an important
role in neuronal development and of these, purinergic recep-
tors are important regulators of neuronal development in the
context of neuron–glia interaction. The signaling pathways con-
trolled by these GPCRs receptors are not completely deciphered,
Frontiers in Cellular Neuroscience www.frontiersin.org October 2013 | Volume 7 | Article 197 | 1
“fncel-07-00197” — 2013/10/25 — 11:25 — page 2 — #2
del Puerto et al. Purinergic control of neuronal development and disease
although it has been demonstrated that they selectively activate
different sets of heterotrimeric G proteins. In addition, these
GPCRs control neuronal development by acting synergistically, in
conjunction with growth factor receptors. While some signaling
pathways and trophic factors have been studied extensively during
neuronal development, the role of othermolecules and their recep-
tors secreted by glia and/or neurons require need further study to
fully understand their participation in the modulation of signal-
ing pathways, as is the case of the components of the purinergic
system.
EXPRESSION OF PURINES AND PURINERGIC RECEPTORS IN
GLIAL CELLS AND NEURONS
In the nervous system, ATP fulﬁls a relevant role in the regulation
of several physiological functions involving neuron–glia signal-
ing networks. For example, ATP modulates synaptic transmission
and a multitude of trophic effects, such as neural cell growth and
development. In neurons, ATP is not only released by the pre-
synaptic terminal, it can also be released by the post-synaptic
membrane (Vizi et al., 1992; Sawynok et al., 1993). In glial cells,
several studies show that astrocytes and other glial cells contain
the machinery necessary to release ATP (Fields and Stevens, 2000)
and there is considerable evidence that glial ATP release is impor-
tant in glia–glia and neuron–glia communication (for review see
Koles et al., 2011). Moreover, theATP secreted by neurons and glial
cells also contributes to various pathological disorders (Burnstock
et al., 2011b), such as hypoxia or other types of brain damage.
In fact, millimolar concentrations of ATP can be generated in
the extracellular milieu of a cell when it dies, which can activate
protective, regenerative and also harmful mechanisms (Cook and
McCleskey, 2002; Volonte et al., 2003; Koles et al., 2005; Franke
et al., 2006b; Burnstock, 2007).
These multiple effects of ATP are not only regulated by
purinergic receptors but also, by extracellular ectonucleotidases
capable of regulating extracellular ATP, ADP, AMP, and adeno-
sine concentrations (Zimmermann et al., 2012). This regulated
variation in purine concentrations makes the purinergic sys-
tem an important mechanism to modulate different activities in
neurons and glial cells. Thus, deregulation of the purinergic sys-
tem can clearly be involved in nervous system pathologies. The
large number of purinergic receptors identiﬁed and the differ-
ent signaling pathways modulated by them makes this system
particularly complex. This extraordinary combination of fac-
tors expands the functional relevance of purinergic signaling
(Figure 1).
Extracellular nucleotides act through an extended family of
nucleotide receptors that can be divided into two families acti-
vated by adenosine or ATP/ADP nucleotides, respectively: the
P1 and P2 receptors. Four different subtypes of GPC adenosine
receptors (P1) have been cloned that are widely expressed in neu-
rons, astrocytes, oligodendrocytes and microglia: A1, A2A, A2B,
and A3 (Dare et al., 2007; Burnstock et al., 2011a). The P2 recep-
tors are subdivided in two different subfamilies, the ionotropic
P2X and the metabotropic P2Y receptors. P2X receptors are lig-
and gated ion channels whose activation by ATP increases Na+,
K+, and Ca2+ permeability, promoting rapid changes in mem-
brane potential (North, 2002; Roberts et al., 2006). All seven
P2X receptors subtypes (P2X1–7) are expressed by neurons and
astrocytes, and some of them are expressed by in oligodendrocytes,
Schwann cells, and microglia. They are each involved in different
processes, such as fast synaptic transmission, synaptic plasticity,
and fast neuronal–glial signaling (Edwards et al., 1992; Silinsky
et al., 1992; Pankratov et al., 1998, 2002, 2009; Burnstock et al.,
2011a; Lalo et al., 2011). By contrast, P2Y metabotropic recep-
tors are related to more long-lasting and trophic functions. Eight
P2Y receptors subtypes have been identiﬁed and they are activated
by different extracellular nucleotides: P2Y1, P2Y12, and P2Y13
are preferentially activated by ADP; P2Y2 and P2Y4 by ATP/UTP;
P2Y6 by UDP; P2Y11 by ATP; and P2Y14 by UDP-sugars (Burn-
stock, 2007). However, the sensitivity of each receptor for a speciﬁc
nucleotide depends on the mammalian species investigated. Thus,
typically, P2Y1, P2Y2, P2Y4, and P2Y6 are coupled to Gq pro-
teins and activate phospholipase C, whereas P2Y12, P2Y13, and
P2Y14 couple to Gi proteins, which results in the inhibition of
adenylyl cyclases and the reductionof intracellular cAMP(Abbrac-
chio et al., 2006). Most of these receptors are expressed in the
nervous system, including neurons and glial cells in central and
peripheral nervous system (CNS and PNS), and they are gener-
ally considered to be involved in bi-directional neuronal–astroglial
communication, exerting long-term effects on proliferation, dif-
ferentiation, migration, and apoptosis (Neary and Zimmermann,
2009; Verkhratsky et al., 2009; Burnstock et al., 2011b).
Glial cells in the CNS express different purinergic receptors
(for an extensive review, see Burnstock and Knight, 2004). Brieﬂy,
CNS astrocytes express P2X1, P2X2, P2X3, P2X4, P2X5, and
P2X7 receptors, although only the P2X1/P2X5 and P2X7 receptors
have been attributed a functional role (Lalo et al., 2008; Naga-
sawa et al., 2009). They also express P2Y1, P2Y2, P2Y4, P2Y6,
P2Y12, and P2Y14 receptors (Fischer et al., 2009), and functional
adenosine receptors (A1,A2A,A2B,A: Brodie et al., 1998; Biber et al.,
1999; Trincavelli et al., 2004; Wittendorp et al., 2004). Microglial
cells are characterized by the predominant expression of func-
tional P2X4 and P2X7 receptors, yet they also express P2Y1,
P2Y2, P2Y2/4, P2Y6, and P2Y12 receptors (Sperlagh and Illes,
2007). Of these, P2Y6 and P2Y12 are functionally relevant to
microglia cells (Boucsein et al., 2003; Sasaki et al., 2003; Inoue,
2008). Oligodendrocytes progenitors are characterized by the
functional expression of P2X7, P2Y1, P2Y2, P2Y4, P2Y6, P2Y11,
and P2Y13 receptors, and there is evidence that they express
mRNA encoding all the adenosine receptor subtypes, even though
functional expression of only the A1 receptor has been identi-
ﬁed in myelinating mature oligodendrocytes (Othman et al., 2003;
Agresti et al., 2005a,b; Fields and Burnstock, 2006). Thus, the
complexity of the purinergic system is even higher when we take
in account the existence of these distinct receptor combinations
during development, as well as in physiological and pathological
states.
In neurons, P2X3 receptors have been identiﬁed in some sin-
gle rat midbrain synaptic terminals (Diaz-Hernandez et al., 2001),
as well as in the central terminals of dorsal root ganglion neu-
rons (DRGs) in the dorsal horn of the spinal cord (Vulchanova
et al., 1997). Other P2X receptors, such as P2X2 and P2X4, are
widely distributed in neuronal structures, including the cortex,
hippocampus, cerebellum, spinal cord, and different brain nuclei
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FIGURE 1 |The coordinated action of glial and neuronal purinergic
receptors and purines in the CNS. Pre-synaptic terminals exocytotically
release both glutamate (GLUT) and ATP as co-transmitters. Extracellular
ATP is broken down by ectonucleotidases to ADP and adenosine (ADO),
with ATP and ADP acting post-synaptically on P2X and P2Y receptors
subtypes, while glutamate acts post-synaptically on α-amino-3-hydroxy-
5-methyl-4-isoxazole propionic acid receptors (AMPARs) and/or
N -methyl-D-aspartate receptors (NMDARs). Conversely, the ATP released
and its breakdown products, ADP and adenosine (ADO), also act
pre-synaptically to modulate neurotransmitter release through the activation
of P2X, P2Y, and P1 (A3) receptors. Resting microglia express the P2X4
and P2X7 receptors that are involved in neuropathic pain. ATP promotes
IL-1β release through P2X7 receptors and it leads to the release of
brain-derived neurotrophic factor (BDNF) through the activation of P2X4
receptors that acts on TrkB receptors expressed by neurons in the pain
pathway. P2X7 and P2Y1 receptors mediate the migration of resting
microglia after injury, whereas the P2Y6 receptors expressed on the
activated microglia mediate phagocytosis at the site of damage. ATP is
also released from astrocytes, together with glutamate and GABA,
modulating neuronal activity. Leukaemia inhibiting factor (LIF) is released
by astrocytes in response to ATP and it promotes myelination by
oligodendrocytes through P2Y1 receptors. The P2X7 receptors on
oligodendrocytes mediate apoptosis while ADO protects them through the
P1 receptor (adapted from Burnstock, 2008).
(Kanjhan et al., 1999; Norenberg and Illes, 2000; Bo et al., 2003).
Moreover, P2X7 receptors have been identiﬁed in pre-synaptic
terminals (Atkinson et al., 2004) and axonal growth cones (Diaz-
Hernandez et al., 2008; del Puerto et al., 2012). There is strong
evidence that P2X7 receptors inﬂuence neuron activity (Sper-
lagh et al., 2006; Diaz-Hernandez et al., 2008; Carrasquero et al.,
2009; Norenberg et al., 2010; Oliveira et al., 2011; del Puerto et al.,
2012), and theymay coordinatemicroglial and neuronal/astroglial
responses, both under physiological and pathological conditions
(Fields and Stevens, 2000; Ferrari et al., 2006; Sperlagh et al.,
2006). With regards the P2Y receptors, P2Y1 receptors are those
dominantly expressed in neurons, while P2Y2 receptors are also
expressed at lower levels in all regions. In addition, P2Y4, P2Y6,
P2Y11, P2Y12, P2Y13, and P2Y14 receptors have been seen to be
differentially expressed in several types of neurons (Moore et al.,
2001; Verkhratsky et al., 2009).
In the PNS, glial cells and neurons also express different
purinergic receptors, the combination of which depends on the
neuronal and glial cell type and function (Fields and Stevens,
2000). For example, non-myelinated Schwann cells express A2A,
A2B, P2X7, P2Y1, and P2Y2 receptors, although only P2X7 and
P2Y2 receptors are functional in myelinating Schwann cells.
PURINERGIC RECEPTORS AND PURINES IN NEURON–GLIA
INTERACTIONS DURING NEURONAL DEVELOPMENT AND
PHYSIOLOGY
The differential expression of purinergic receptors during neu-
ronal and glial development, in combinationwith themechanisms
that control extracellular purine concentrations, establishes the
purinergic system as a global mediator of nervous system plastic-
ity capable of regulating different developmental and functional
events, from neurogenesis to neuronal excitability.
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NEUROGENESIS
Different types of glial cells participate in the generation of new
neurons in the brain, both during development and at adult stages.
These new neurons are generated in neurogenic “niches” that can
be considered as functional units of cells, many of which are
glial (astrocytes, microglia, etc.), and they are orchestrated by
secretedmolecules and the extracellularmatrix. In the adult rodent
brain neurogenesis occurs in two main regions, the subventricular
zone (SVZ) of the lateral ventricles and the dentate gyrus of the
hippocampus (Altman and Das, 1965; Gage et al., 1998; Alvarez-
Buylla and Garcia-Verdugo, 2002). Four types of stem-like cells
have been identiﬁed in the SVZ: type E cells or ependymal ciliated
cells; slow proliferating type B cells (nestin and GFAP positive
cells); type C cells or transit amplifying progenitors (nestin posi-
tive cells); and proliferating type A neuroblasts. These neurogenic
regions are associatedwith themicrovasculature inwhat is denom-
inated the perivascular niche for neurogenesis (Palmer, 2002). In
this region, both angiogenesis and neurogenesis are closely related.
Different types of cells in these perivascular neurogenic niches
inﬂuence the generation and differentiation of new neurons, such
as astrocytes, astrocyte-like stem cells, microglia, or endothe-
lial cells, acting through cell–cell interactions, or the secretion
of trophic factors, neurotransmitters, hormones, etc. (Doetsch,
2003; Alvarez-Buylla and Lim, 2004; Abrous et al., 2005). These
effects are reciprocal and accordingly, neurons contribute to the
differentiation of glial cells, such as oligodendrocytes (Song et al.,
2002). Moreover, it is possible that the heterogeneity of glial cells
in the brain may go some way to explain the variation in different
neurogenic regions.
There is now new evidence demonstrating a role for purines
and purinergic receptors in the regulation of neurogenesis. It is
widely known that extracellular ATP is one of the main regula-
tors of embryonic neurogenesis through the activity of the P2Y1
receptor. In radial glia ﬁbers, P2Y1 activation induces intracel-
lular inositol triphosphate-mediated Ca2+ release that provokes
the liberation of growth factors, ATP, and other neurotransmitters
to the extracellular environment (Wiencken-Barger et al., 2007;
Elias and Kriegstein, 2008). ATP released from radial glia acti-
vates P2Y1 receptors in the neighboring cells, thereby generating
calcium waves that extend from the ventricular zone to the pia,
expanding across the entire thickness of the embryonic cortex.
The formation of these calcium waves between radial glia ﬁbers
promotes the proliferation of neuronal progenitors and their syn-
chronization in the S phase of the cell cycle, and indeed, the
non-speciﬁc purinergic P2 receptor antagonist, suramin, causes
a reduction in cell proliferation in the ventricular zone (Weissman
et al., 2004). Thus, purinergic signaling represents an important
element involved in the maintenance of the neuronal progenitor
pool during cortical neurogenesis. Subsequent studies on cul-
tured neurospheres have characterized the purinergic signaling
components involved in these events. P2X4, P2X7, P2Ys, and
adenosine receptor mRNA has been shown to be expressed in neu-
rospheres (Stafford et al., 2007; Grimm et al., 2009) and moreover,
mitotically active neurospheres secrete ATP and undergo puriner-
gic receptor-activated calcium mobilization, suggesting a role for
purines andpurinergic receptors in the regulationof neuronal pro-
genitor expansion (Lin et al., 2007; Stafford et al., 2007). Adenosine
is also implicated in the regulation of neurosphere proliferation
in a two ways. While on the one hand the A1 receptor activates
MEK/ERK and Akt signaling pathways (Migita et al., 2008), A2a
receptor activation inhibits neurosphere proliferation (Stafford
et al., 2007).
Purinergic signaling is also coordinated with growth factor
signaling during neurogenesis. For example, epidermal growth
factor (EGF) activates the same intracellular signaling cues as
P2Y1 and P2Y2 receptor agonists (Lin et al., 2007; Stafford et al.,
2007; Grimm et al., 2009), suggesting that EGF and purinergic
signaling must be coordinated during neurogenesis. Accordingly,
cell proliferation is diminished in neurospheres of P2Y1 knock-
out mice despite the presence of growth factors (Mishra et al.,
2006).
ATP release and purinergic signaling may not only be required
for developmental neurogenesis but also, for the progenitor
cell proliferation that persists in the adult brain. Ectonucleoti-
dase activity is high in the vascular beds subserving both the
subventricular and subgranular zones, the two major neuro-
genic niches in the adult forebrain (Lin et al., 2007). Speciﬁcally,
the CD39L1 nucleotide triphosphate dinucleotide phosphorylase
(NTPDase-2) is expressed in perivascular astrocytes in neurogenic
regions, which means that ADP can activate P2Y receptor sig-
naling in the adjacent neuronal precursors (Braun et al., 2003).
NTPDase-2 is also expressed in slow proliferating precursor stem
cells (type B cells) of the SVZ, in glial tube cells of the ros-
tral migratory stream (RMS; Braun et al., 2003; Langer et al.,
2007), as well as in neuronal precursor cells in the hippocam-
pus where it co-localizes with P2Y receptors (Braun et al., 2003;
Shukla et al., 2005). Another ectonucleotidase, tissue-non-speciﬁc
alkaline phosphatase (TNAP), which produces adenosine from
extracellular ATP, is expressed by cells of the SVZ and throughout
the RMS suggesting a possible role of adenosine receptors in adult
neurogenesis (Langer et al., 2007). Finally, functional expression
of P2X receptors is detected in hippocampal neural progenitor
cells, as reﬂected by inward currents, membrane depolarization,
as well as transient increases in intracellular Ca2+ concentrations
(Hogg et al., 2004; Shukla et al., 2005).
In conclusion, ectonucleotidase signaling can negatively reg-
ulate purinergic signaling, clearing ATP in order to prevent
uncontrolled expansion of progenitor cells and establishing a per-
missivemicroenvironment for neuronal differentiation.Moreover,
the association of NTDPase-2 activity with the capillary microvas-
culature suggests that purinergic signaling may contribute to the
angiogenic support of adult neurogenesis (Goldman and Chen,
2011). These data show that the speciﬁc regulation of purinergic
signaling is crucial for both embryonic neurogenesis during early
brain development and to maintain of the neurogenic niches in
the adult brain.
NEURONAL MIGRATION
Neurons born in the ventricular zone of the neural tube popu-
late distant regions of the CNS that are reached by radial and
tangential migration (Hatten, 1999). ATP and P2Y1 receptor are
involved in the intermediate migration of neuronal progenitors
to the neocortical SVZ of developing brain (Liu et al., 2008). It
has been shown that the P2Y1 receptor is expressed in cells of the
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ventricular and SVZ, and that its stimulation with ATP propagates
Ca2+ waves in these cells that can be blocked by the P2Y1 antago-
nist,MRS-2179 (Liu et al., 2008). Other studies have demonstrated
that reduced P2Y1 receptor expression alters the calcium signal-
ing in neural progenitor cells and their migration (Scemes et al.,
2003). Migration during adult neurogenesis is also regulated by
nucleotides like ATP, ADPβS, or UTP, which in combination with
EGF increase focal adhesion kinase (FAK) and Akt phosphory-
lation in neurospheres isolated from the SVZ. This intracellular
signaling contributes to the reorganization of the actin cytoskele-
ton and drives the migration of neural precursors (Grimm et al.,
2010).
AXON GROWTH
Once neurons or neuronal precursors are generated they must
not only migrate to their ﬁnal destination but they must also
extend their axons to contact their targets. Glial cells fulﬁll an
important role in regulating axon growth, both during develop-
ment and regeneration. Different secreted and extracellularmatrix
molecules can guide axons and control their growth rate. Indeed,
many studies have described essential roles for neurotrophic fac-
tors in axon growth andneuronal survival (e.g.,NGF,BDNF,NT-3,
FGFs, IGF-I, etc.). As mentioned above, these factors control the
activity of PI3-kinase, which is essential for axons to develop and
elongate. PI3-kinase activity can be regulated through different
membrane receptors and adhesion molecules, and recent studies
identiﬁed a role for purines and purinergic receptors in the mod-
ulation of signaling pathways involved in axonal growth, such as
that mediated by PI3-kinase.
ATP can be stored and released into the extracellular envi-
ronment from neurons and glial cells, such as astrocytes, in
physiological and pathological conditions (Coco et al., 2003;
Pankratov et al., 2006; Thompson et al., 2006; Bowser and Khakh,
2007). In the extracellular environment ATP can be degraded by
extracellular ectonucleotidases, which not only control the aver-
age half-life of nucleotides but also, they generate new agonists
for the different purinergic receptors, such as ADP or adenosine
(Zimmermann, 2000). The amount and combination of different
purines in the extracellular region during development can regu-
late the formation and growth of neuronal compartments. During
development ATP can be released by different cell types, or liber-
ated after programed or necrotic cell death, generating gradients
that canmodulate axonal growth and pathﬁnding. Moreover, large
amounts of ATP can be liberated into the extracellular milieu in
pathological conditions, impairing regenerative processes in neu-
rons. Our recent studies show that hippocampal neurons express
P2X7, P2Y1, and P2Y13 receptors in the distal domain of axons
and that ATP acts as a negative regulator of axon growth during
axonal elongation, promoting a decrease in axon length in neu-
rons cultured in the presence of ATP. ATP produces an increase
of intracellular Ca2+ in the distal axon of cultured hippocam-
pal neurons, acting through P2X7. The decrease in axon length
can be reversed by treating hippocampal neurons with a speciﬁc
P2X7antagonist, brilliant blueG(BBG)orusingP2X7 interference
RNA. Indeed, BBG impaired the ATP dependent increase of intra-
cellular Ca2+ in the distal region of the axon (Diaz-Hernandez
et al., 2008).
By contrast, the product of ATP degradation, ADP, promotes a
signiﬁcant increase in axon length (del Puerto et al., 2012). ADP
is the main agonist of three P2Y receptors, P2Y1, P2Y12, and
P2Y13. P2Y1 and P2Y13 are expressed in hippocampal neurons
(Csolle et al., 2008; del Puerto et al., 2012), whereas P2Y12 has
been described in rat brainstem, DRGs (Heinrich et al., 2008),
and oligodendrocytes (Amadio et al., 2006), yet it is absent from
hippocampal and neocortical neurons (Hollopeter et al., 2001).
Although P2Y1 and P2Y13 are activated by the same agonist, they
produce opposite effects on axon elongation: P2Y1 is a positive
regulator of axonal growth while P2Y13 negatively regulate this
process (del Puerto et al., 2012).
These twoADPactivatedmetabotropic receptors, togetherwith
the ionotropic P2X7 receptor, share a common signaling pathway
that involves type 5 adenylyl cyclase (AC5), and thus, they con-
trol of cAMP levels, an important second messenger involved
in axon formation and elongation (Shelly et al., 2010). In our
model, P2Y1 produces an increase in axon length by activating
Gq proteins and AC5, the latter promoting an increase in cAMP
in the axonal growth cone, which can be abolished by expos-
ing neurons to the speciﬁc AC5 inhibitor, NKY80. By contrast,
P2Y13 is coupled to a Gi protein that inhibits AC5 activity, thereby
decreasing the cAMP concentration in the axon growth cones and
generating shorter axons (del Puerto et al., 2012). Finally, AC5 is
inhibited by submicromolar concentrations of Ca2+ (Willoughby
and Cooper, 2007), such as those produced by P2X7 activation,
thereby provoking negative effects on axon elongation (del Puerto
et al., 2012).
This coordinated signaling through AC5 serves to modu-
late one of the main pathways that controls neuronal polarity
and axonal elongation, the PI3K-Akt-GSK3α/β signaling pathway
(Shi et al., 2003). Modulating P2Y1, P2Y13, and P2X7 activ-
ity induces changes in PI3K activation, and modifying Akt and
GSK3α/β phosphorylation, and promoting or inhibiting axon
growth (Garrido et al., 2007; del Puerto et al., 2012). Thus, extra-
cellular nucleotides released in physiological and pathological
conditions can act in a coordinated way through purinergic recep-
tors expressed by neurons to modify axon growth, promoting
the arrival of axons to their target to form synaptic contacts
(Figure 2).
ROLE OF GLIAL CELLS IN THE GENERATION OF FUNCTIONAL
AXONAL DOMAINS
After axons have grown and reached their targets, glial cells con-
tribute to neural activity by enveloping and myelinating axons,
generating nodes of Ranvier and their adjacent structures, and
providing an electrical insulation for the rapid conductionof nerve
impulses. This role is achieved by oligodendrocytes in CNS and
Schwann cells inPNS.Axon ensheathingdepends onbi-directional
signals between myelinating glia and neurons, whereby neuronal
activity leads to the release of soluble factors that are detected
by myelinating glia. Conversely, myelinating glia interact with
axons and thereby communicating with neurons. This interaction
is maintained by molecules in the membranes of both cell types,
which are differentially distributed in paranodes, juxtaparanodes,
and nodes of Ranvier, and that can modulate signaling cascades
and speciﬁcally concentrate ion channels at nodes of Ranvier or
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FIGURE 2 | Modulation of axon growth by purinergic receptors.
(A) Schematic representation of the coordination of purinergic receptors and
purines during the modulation of axon elongation in hippocampal neurons.
Both ADP acting on P2Y1 and P2Y13 receptors, and ATP acting through P2X7
receptors, modulate adenylyl cyclase type 5 activity (AC5) in a coordinated
manner. This coordinated signaling through AC5 serves to modulate cAMP
intracellular concentrations and the activity of the PI3K-Akt-GSK3α/β signaling
pathway, the latter controlling axon elongation in hippocampal neurons
(adapted from del Puerto et al., 2012). (B) Axon elongation depends on the
extracellular concentration of ATP. High extracellular concentrations of ATP
provoked by cell damage, programed apoptosis, or other physiological and/or
pathological conditions diminish axon elongation. However, in the absence
of high extracellular concentrations of ATP, ADP can trigger P2Y1 receptors
and promote axon elongation. The balance between the extracellular
concentrations of purines and the activity of purinergic receptors modulates
axonal elongation.
the axon initial segment (AIS). For example, L1 homophilic inter-
actions between axons and Schwann cells are essential for the
initiation of myelination and the expression of these molecules
can be regulated by neuronal activity (Seilheimer et al., 1989;
Wood et al., 1990). In fact, impairing sodium-dependent action
potentials with tetrodotoxin (TTX), inhibits axon myelination
in an “in vitro” model of cultured glial cells and neurons, as
occurs in the developing optic nerve after intravitreous injection
of TTX. By contrast, the α-scorpion toxin-mediated increase in
neuronal ﬁring enhancesmyelination (Demerens et al., 1996). Dif-
ferent adhesion molecules and growth factors have been proposed
to act as intermediate molecules between neuronal activity and
myelination, although many details of the mechanisms regulating
myelination remain uncertain.
Regarding purinergic signaling, studies in DRG neurons show
that neuronal activity releases ATP from premyelinated axons,
which can be detected by several purinergic receptors in myelinat-
ing glia. ATP inhibits differentiation and myelination by Schwann
cells through the activation of P2Y receptors on Schwann cells
(Stevens and Fields, 2000). As purinergic receptors expression is
developmentally regulated, this inhibition of Schwann cells dif-
ferentiation and myelination may help to coordinate Schwann
cell development with functional activity in the nervous system,
thereby preventing premature Schwann cell differentiation. How-
ever, another purine, adenosine, stimulates differentiation of
oligodendrocyte precursors and myelination in the CNS. These
differential effects of purines in the PNS and CNS are proba-
bly due to differential expression of purinergic receptors, as well
as that of related trophic factors and adhesion molecules. To
understand the role of purinergic signaling in myelination, it is
necessary to clearly identifywhich receptors are expressed inmyeli-
nating glial cells at each developmental stage. This will also help
understand which of these receptors are involved in demyelinating
diseases. For example, the P2X7ATP receptor seems to be involved
in the myelin defects associated with experimental autoimmune
encephalomyelitis (EAE) or Charcot–Marie–Tooth (CMT) disease
(Sharp et al., 2008; Nobbio et al., 2009). Moreover, a molecule able
to regulate P2X7 expression, like retinoic acid (Wu et al., 2009), can
also regulate myelination (Latasa et al., 2010; Huang et al., 2011).
All these data support an important role of purines and puriner-
gic receptors in functional axonal maturation, and they emphasize
the importance of future studies regarding the role of purinergic
receptors in axon development and the functional maturation of
axonal domains, like the nodes of Ranvier or AIS.
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NEURONAL ACTIVITY
In the developing nervous system, neuronal activity plays a major
role in neuronal development, regulating axonal pathﬁnding, the
reﬁnement of topographic maps, dendrite morphogenesis, and
the segregation of axonal terminal arbors. Glial cells participate
in all these processes and modulate neuronal activity. As men-
tioned above, ATP is released by neurons and astrocytes (Fields
and Stevens, 2000) and this extracellular ATP can either bind
directly to P2 receptors, or it may be processed by ectonucleoti-
dases in the extracellular space to generate other purines, such
as ADP or adenosine. These purines each have speciﬁc afﬁni-
ties for different purinergic receptors. For example, P2Y receptors
show ATP sensitivity at nanomolar concentrations, while P2X7
receptors require micromolar concentrations of this purine (Sur-
prenant, 1996), giving ATP signaling a very dynamic range of
activities. ATP release fromastrocyteswas initially found in culture
systems (Queiroz et al., 1997) and its physiological signiﬁcance
was deduced from the analysis of propagating glial Ca2+ waves
(Arcuino et al., 2002). Thus, this ATP release is able to modulate
neuronal activity (Koizumi et al., 2003).
Initial experiments showed that ATP depolarizes neurons (Jahr
and Jessell, 1983; Krishtal et al., 1983), subsequently opening
single ion channels (Kolb and Wakelam, 1983; Benham and
Tsien, 1987), and mediating synaptic transmission at synapses
in both the PNS and CNS (Jansen et al., 1990; Edwards et al.,
1992; Evans et al., 1992; Silinsky et al., 1992). For example,
ATP receptor activation potentiates a voltage-dependent calcium
channel in CA3 hippocampal neurons (Dave and Mogul, 1996).
Similarly, P2Y1 receptors mediate the activation of neuronal
calcium-dependent potassium channels (Schicker et al., 2010),
while different P2Y receptors can inhibit two-pore potassium
(K(2P)) channels (Shrestha et al., 2010), Kv7 potassium channels
(Hernandez et al., 2008), and Cav2 calcium channels (Filippov
et al., 2010). Thus, purinergic signaling is an important modulator
of neuronal activity and as such, it will be important to study and
understand the intracellular molecular mechanisms that control
neuronal excitability through purinergic signaling. Large amounts
of ATP seem to be released after an action potential (Richler et al.,
2008) that binds to extrasynaptic P2X receptors expressed at den-
dritic spines and nerve terminals (Vulchanova et al., 1996; Le et al.,
1998; Rubio and Soto, 2001). This action of ATP is neuromodula-
tory but no evidence has been found for a role of ATP in generating
action potentials. Most evidence of the neuromodulatory activity
of purinergic receptors and purines has come from the PNS. How-
ever, pre-synaptic P2X responses have nowbeen described inmany
parts of the brain and for example, it has been shown that P2X4
may play a role in fast synaptic transmission or in the modulation
of neurotransmitter release (Norenberg and Illes, 2000; Rubio and
Soto, 2001).
THE RELATIONSHIP BETWEEN GLIAL AND NEURONAL CELLS
IN NERVOUS SYSTEM PATHOLOGIES
Deregulation of physiological of purines and purinergic receptors
functions in neurons and glial cells have been described inmultiple
pathologies in central and peripheral nervous system, including
psychiatric and neurodegenerative diseases, and brain damage due
to trauma or ischemia.
EPILEPSY
Extracellular nucleotides and purinergic receptors are involved in
epileptic seizures. In the hippocampus of different animal models
of epilepsy an increase in the expression and activity of different
extracellular ectonucleotidases has been described, such as NTP-
Dase 2 and 3, and ecto-5′-nucleotidase (Schoen et al., 1999; Oses
et al., 2004; Cognato Gde et al., 2007), as well as an increase in
the extracellular concentration of ATP (Wieraszko and Seyfried,
1989), which would be rapidly broken down to adenosine. In
fact, the hydrolysis rates of ATP, ADP, and AMP is signiﬁcantly
enhanced in the serum of patients following an epileptic event
(Grosso et al., 2009). Some studies propose that an increase in
the density of A1 receptors in the cortex and hippocampus may
underlie a reduction in the seizures provoked by chronic NMDA
receptor stimulation by glutamate released from astrocytes (Von
Lubitz et al., 1995; Tian et al., 2005). On the other hand, astro-
cytes also regulate the endogenous anticonvulsant effectsmediated
by adenosine in the brain, since synaptic levels of adenosine are
controlled by an astrocyte-based adenosine cycle in which a key
element is the activity of the enzyme that removes adenosine, the
adenosine kinase (ADK; Etherington et al., 2009). In addition to
the involvement of adenosine in epileptic seizures, the role of ATP
andADPhas alsobeen studied. Indeed, the amountof extracellular
ATP detected in hippocampal slices following electrical stimula-
tion of Schaffer collaterals is signiﬁcantly greater in mice with
inherited susceptibility to seizures than in those that are resistant
(Wieraszko and Seyfried, 1989).
It has also been shown that P2X7 receptors are involved in
epileptic seizures since the hippocampus of chronic epileptic rats
respond abnormally to ATP in association with an increase in the
expression of this receptor. P2X7 is also up-regulated, probably
in microglia, and it is involved in the inﬂammatory reaction of
epilepsy and may participate in the pathophysiology of tempo-
ral lobe epilepsy (Vianna et al., 2002). In fact, kainate-induced
seizures result in an elevation of the levels of the P2X7 receptor on
microglia as they become activated (Rappold et al., 2006). More-
over, signiﬁcantly elevated P2X7 immunoreactivity in amoeboid
or phagocytoyic microglia appeared in the dentate gyrus 7 days
after status epilepticus (Kim et al., 2009). In conclusion, extracel-
lular nucleotides are involved in the modulation of epilepsy and
seizures, and they contribute to the activation of purinergic recep-
tors on both astroglial cells and microglia in the epileptic brain,
affecting neuronal function.
BRAIN TRAUMA, HYPOXIA, AND STROKE
It has well documented that mechanical trauma or metabolic
limitation, such as trauma, ischemia and stroke, results in an
immediate, irreversible loss of tissue at the lesion site, aswell as sec-
ondary expansion of tissue damage over time. This type of injury
promotes the release of ATP/adenosine from different cells aggra-
vating the neuronal and glial damage in the surrounding zone.
“In vivo” studies using models of focal ischemia, as well as, dif-
ferent models of mechanical injury to the rat nucleus accumbens
and the spinal cord, described sustained high release of ATP and
glutamate in the peri-traumatic area (Wang et al., 2004; Melani
et al., 2005; Franke et al., 2006a; Frenguelli et al., 2007). During
ischemia and mechanical injury the ATP released is sufﬁcient to
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stimulate P2X7 receptors and to kill neurons, an event which can
be blocked by P2X7 antagonists like BBG (Arbeloa et al., 2012).
Indeed, BBG also promotes the recovery of motor function after
mechanical injury to the rat spinal cord (Wang et al., 2004; Peng
et al., 2009) and reduces the secondary damage in the mechani-
cal injured brain (Kimbler et al., 2012). Nevertheless, extracellular
ATP can also modify synaptic transmission in neurons, affect-
ing their viability. Extracellular ATP released from damage cells
can stimulate the pre-synaptic neuronal P2X receptors, promot-
ing enhanced excitatory synaptic transmission (Rodrigues et al.,
2005; Zhang et al., 2006; Sperlagh et al., 2007). Meanwhile, activa-
tion of P2X7 receptors by ATP in astrocytes may not only permit
the release of ATP but also, that of glutamate and GABA in
the peri-traumatic area (Pannicke et al., 2000; Wang et al., 2002;
Duan et al., 2003). Hence, the hypoxic release of ATP may exert
both excitatory and inhibitory effects on neurons, aggravating
or diminishing the metabolic damage exerted on neurons and
astrocytes.
P2Y1 expression is also enhanced around necrotic tissue, in
the peri-traumatic area of the rat cortex and nucleus accumbens
after mechanical injury, and in the pre-infarct region after middle
cerebral artery occlusion (MCAO; Franke et al., 2004b). In fact, a
non-selective P2 receptor antagonist, PPADS, improved the mor-
phological and functional alterations provoked by the ischemic
injury (Lammer et al., 2006), leading to a decrease in the infarct
volume and reducing neuronal and astrocyte death for up to 7 days
after MCAO (Lammer et al., 2011). Other studies have shown
that intra-cerebroventricular administration of the P2Y1 agonist,
MRS-2365, increases cerebral infarct volume after 72 h of transient
MCAO, whereas the P2Y1 antagonists MRS-2179 and MRS-2279
reduced this volume, aiding the recovery of motor coordination
(Kuboyama et al., 2011). As mentioned previously, P2Y1 receptors
are expressed by astrocytes and they can protect against hydrogen
peroxide-induced damage (Fujita et al., 2009). Cytotoxic edema
and the magnitude of ischemic lesions are signiﬁcantly reduced by
treatment with a P2Y1 agonist, 2-MeSADP), and this protection is
achieved by enhanced astrocyte mitochondrial metabolism due to
increased inositol trisphosphate-dependent Ca2+ release (Zheng
et al., 2010). However, inhibition of astrocyte P2Y1 receptors can
also result in cytokine/chemokine transcriptional suppression,
involving the NF-kB pathway, and brain protection (Kuboyama
et al., 2011). The P2Y1 receptor is also thought to play a role in
the production of GFAP and GDNF in astrocytes under transient
MCAO (Sun et al., 2008), and it participates in astrogliosis (Franke
et al., 1999,2001,2004b,2009). This is due toP2Y1-mediatedmod-
ulation of PI3K/AKT and MAPK/ERK signaling in astrocytes and
neurons, resulting in astroglial proliferation and anti-apoptotic
processes (Franke et al., 2009). A protective effect of theA2A recep-
tor agonist has been described in mechanical injured spinal cord
and during ischemia, most probably due to the reduction of glu-
tamate outﬂow from glial cells (Popoli et al., 2003; Pedata et al.,
2007). However, A2A receptor inhibition could be protective in
a model of permanent focal ischemia, probably by attenuating
microgliosis and the production of pro-inﬂammatory cytokines
(Chen and Pedata, 2008). Among these glial cells, microglia are
activated by ATP released after mechanical trauma or metabolic
limitation and stimulation of P2X7 in microglia is deleterious in
cultured neurons as a consequence of oxidative stress, although
this effect is halted in microglia that lack this receptor subtype
(Skaper et al., 2006). In fact, P2X7 expression and activation
in microglia after mechanical injury or metabolic limitation in
the penumbra surrounding the necrotic region, is an early reac-
tion, followed by the appearance of these receptors in astroglia
and at pre-synaptic elements of neurons (Franke et al., 2004a,
2007).
Hypoxic ischemic injury also affects oligodendrocytes and the
white matter. In general, the ATP released from damage cells
during the ischemic process facilitates P2X7 activation in oligo-
dendrocytes, promoting the inward currents and cytosolic Ca2+
overload that lead to oligodendrocyte death (Domercq et al.,
2010). In contrast to what occurs in astrocytes and neurons,
hypoxic/ischemic insults might down-regulate P2X7 expression
in cultured oligodendrocytes (Wang et al., 2009). Thus, activa-
tion of purinergic receptors by ATP released after trauma leads
to late responses of glial cells, such as astroglia proliferation,
microglia activation, and demyelination in the white matter,
which modiﬁes neuronal transmission and viability during these
pathologies.
MULTIPLE SCLEROSIS AND AMYOTROPHIC LATERAL SCLEROSIS
Demyelination in multiple sclerosis (MS) and amyotrophic lat-
eral sclerosis (ALS) involves purinergic receptors signaling, since
the nucleotides released in large quantities under inﬂammatory
conditions and following cell death are important mediators in
demyelinating diseases. Up-regulation and activation of the A1
adenosine receptor attenuates neuroinﬂammation and demyeli-
nation during chronic EAE, a model of MS (Tsutsui et al., 2004).
This effect is related to pro-myelinating effect of A1 receptors
in oligodendrocyte precursors. ATP signaling is also implicated
in this pathology through the activation of the P2X7 receptor in
oligodendrocytes that causes excitotoxicity. Indeed, treatment of
chronic EAE models with a P2X7 antagonist reduces demyeli-
nation and ameliorates the associated neurological symptoms
protecting oligodendrocytes from death (Matute et al., 2007). In
fact, P2X7 null mice do not develop EAE associated symptoms
(Sharp et al., 2008).
In post-mortem sections of the cerebral cortex from MS
patients, the P2Y12 receptor is present in myelin and interlam-
inar astrocytes but absent from demyelinated axons. Decreased
P2Y12 receptor immunoreactivity in the proximity of the lesions
is directly correlated with the extent of demyelination (Amadio
et al., 2010), suggesting that the loss of purinergic P2Y12 receptors
might bedetrimental to tissue integrity. Amarked increase of P2X7
immunoreactivity in reactive astrocytes has also been observed in
brain tissues from MS patients (Narcisse et al., 2005), as well as
in microglial cells/macrophages in affected regions of tissue from
MS andALS patients (Yiangou et al., 2006). Astrocytes, inﬁltrating
cells of the monocyte/macrophage lineage and activated microglia
can release ATP and thereby contribute further to P2X7 activation
and cell death in oligodendrocytes (Matute et al., 2007; Matute and
Cavaliere, 2011).
With regards purinergic signaling andALS, an up-regulation of
P2X4, P2X7, and P2Y6 receptors has been observed in transgenic
mice over-expressing human superoxide dismutase 1 (SOD1), an
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animalmodel of ALS (D’Ambrosi et al., 2009), as well as the down-
regulation of ATP-hydrolyzing activities in microglia, suggesting
that the pro-inﬂammatory actions of microglial P2 receptors are
enhanced in this ALS model. During the progression of ALS,
microglia, astrocytes, and motor neurons might enter in crosstalk
via ATP release/degradation and P2X7 activation, generating a
feedback loop that drives the sustained pro-inﬂammatory and
detrimental response (Amadio et al., 2011; Volonte et al., 2011)
which is prevented by P2X7 antagonists (D’Ambrosi et al., 2009;
Gandelman et al., 2010). However, P2X4 receptors exert protec-
tive effects in motor neurons. In function of these data, low ATP
concentrations protect cells against exocytotoxic stimuli through
P2X4 receptors, whereas high concentrations of ATPproduce toxic
P2X7 activation. Finally, adenosine is also involved in ALS since
adenosine A2A receptor antagonists prevent motor neuron death
(Mojsilovic-Petrovic et al., 2006).
ALZHEIMER’S DISEASE
Recent studies have implicated purinergic receptors in neu-
rodegenerative diseases. For example, there is evidence of the
involvement of purinergic receptors in Alzheimer’s disease (AD),
and A1 receptor expression is lost or reduced in the outer lay-
ers of hippocampal dentate gyrus in human brain tissue from
AD patients (Jansen et al., 1990; Ulas et al., 1993), while the
expression of A1 and A2A receptors appears to be increased
in the frontal cortex (Albasanz et al., 2008). With regards the
involvement of P2 receptors in this pathology, an up-regulation
of the P2X7 receptor occurs around Aβ plaques in a mouse
model of AD (Parvathenani et al., 2003) and enhanced P2X7
expression is detected in brain samples from AD patients, espe-
cially in microglia associated with Aβ plaques (McLarnon et al.,
2006). Moreover, cultured fetal human microglia cells exposed to
the amyloidogenic Aβ1−42 peptide have elevated levels of P2X7
receptors and an increased amplitude in their Ca2+ response,
which can be abrogated by P2X7 inhibitors (McLarnon et al.,
2006). For instance, acting through P2X7 receptors, extracel-
lular ATP can alter β-amyloid peptide-induced cytokine release
frommacrophages andmicroglia,making this receptor subtype an
important modulator of neuroinﬂammation in AD (Rampe et al.,
2004; Sanz et al., 2009). Finally, the up-regulation of P2X7 and
in the production of reactive oxygen species (ROS) in microglia
occurs in parallel with the increase in Aβ, and in relation to the
synaptotoxicity and cerebral damage in an AD model (Lee et al.,
2011). The involvement of the P2X7 receptor in AD is corrob-
orated by the fact that Aβ deposition in an AD mouse model
can be prevented by P2X7 antagonists (Diaz-Hernandez et al.,
2012). Thus, the P2X7 receptor mediates purinergic inﬂamma-
tory responses in the AD brain through its activation in microglial
cells.
Other P2 purinergic receptors have been involved in AD. Aβ
induces a caspase-mediated cleavage of P2X4 receptor in pri-
mary rodent neurons. This P2X4 levels reduction attenuates
Aβ1−42-induced neuronal death, while increased P2X4 expres-
sion in a neuronal cell line enhances Aβ1−42 toxic effect (Varma
et al., 2009). P2Y2 density reduction is correlated with lower
synaptophysin immunoreactivity in post-mortem parietal cor-
tex samples from AD patients (Lai et al., 2008). In addition,
P2Y1 receptors have been also localized in characteristic AD
structures, such as neuroﬁbrillary tangles, neuritic plaques, and
neuropil threads (Moore et al., 2000). Purinergic receptors also
contribute to the AD pathology acting on astrocytes. For exam-
ple, ATP and glutamate released from Aβ25−35 activated astroglial
cells are able to activate neural hemichannels that causes neu-
ral damage (Orellana et al., 2011). In the same way, P2X7
receptors activation in mouse primary astrocytes stimulates the
non-amyloidogenic APP processing by α-secretases and reduces
amyloid plaques (Delarasse et al., 2011; Diaz-Hernandez et al.,
2012).
NEUROPATHIC PAIN
Communication between neurons and surrounding glial cells is
implicated in chronic pain and in fact, neuronal–glia communica-
tion through purinergic signaling is also involved in neuropathic
pain. Adenosine contributes to analgesia due to the combined
actionofA1 receptor-mediated antinociception andA2A receptor-
mediated anti-inﬂammatory activity (Ledent et al., 1997; Johans-
son et al., 2001; Bura et al., 2008). The number of microglia and
astrocytes is enhanced in wild-type mice subjected to sciatic nerve
injury that causes neuropathic pain, and this response is atten-
uated in A2A receptor knockout animals (Bura et al., 2008). In
addition, ATP and P2 receptors have been studied extensively
in neuropathic pain. ATP release from Ca2+ wave propagating
spinal astrocytes could play an important role in the conduc-
tion of nociceptive information, since DRGs respond to ATP by
depolarization and glutamate release (Gu andMacDermott, 1997).
Administration of ATP produces long-lasting allodynia, probably
via P2X2/P2X3 receptors (Nakagawa et al., 2007) and it has been
suggested that P2X3/P2X2/3 receptor-dependent cytosolic phos-
pholipase A2 (cPLA2) activity in primary sensory neurons is a
key event in neuropathic pain (Tsuda et al., 2007). The peripheral
equivalents of astrocytes, satellite glial cells, are located in sen-
sory ganglia and they express functional P2X7 receptors (Zhang
et al., 2005) that can be stimulated by ATP released from DRGs, in
turn causing the release of TNF-α and potentiating P2X3 receptor-
mediated responses in nearby neurons (Zhang et al., 2007). Several
studies have implicated microglial P2X4 receptors in tactile allo-
dynia and hyperalgesia, contributing to the pain states. P2X4
receptor-immunoreactivity is enhanced in spinal microglia after
peripheral nerve injury and intraspinal application of P2X4 recep-
tor antagonists suppresses tactile allodynia (Tsuda et al., 2003).
Signaling between microglia and neurons is therefore an essen-
tial link in neuropathic pain transmission after peripheral nerve
injury. ATP-stimulation of microglia through the P2X4 recep-
tor signals to lamina I neurons and change their phenotype,
causing a collapse of their transmembrane anion gradient. In
addition, BDNF released from microglia after ATP stimulation
provides a crucial signal to neurons during this process (Coull
et al., 2005; Keller et al., 2007). P2X7 activation promotes inﬂam-
mation andneuropathic pain (Donnelly-Roberts and Jarvis,2007).
Indeed, blocking P2X7 receptors provokes anti-nociception that
may be explained by the impairment of pro-inﬂammatory IL-
1β release from macrophages or microglia, and by the absence
of nociceptor activity in peripheral tissues or pain-transmitting
neurons in the CNS (Clark et al., 2010). In addition, IL-1β
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transiently enhances P2X7 receptor expression and activity in
humanastrocytes, forming apositive feedback loop (Narcisse et al.,
2005).
In terms of P2Y metabotropic receptors, P2Y1 receptors
decrease the intensity of pain by blocking voltage-sensitive Ca2+
channels in the central terminals of sensory neurons within the
dorsal horn of the spinal cord and by decreasing the gluta-
mate release from DRG terminals (Gerevich et al., 2004). Recent
studies showed that the P2Y13 receptor can counteract the
neuropathic effect of the P2Y1 receptor (Malin and Molliver,
2010). However, the most studied P2Y receptor in terms of
the pathology of neuropathic pain is P2Y12, the mRNA expres-
sion of which is enhanced in microglial cells in the spinal
cord ipsilateral to the injured nerve after lumbar nerver injury,
a model of neuropathic pain (Tozaki-Saitoh et al., 2008). In
addition, activation of P2Y12 receptors induces the release of
pro-inﬂammatory cytokines that induce neuropathic pain, such
as IL-1β and TNF-α (DeLeo and Yezierski, 2001). P2Y12 recep-
tors are also required for the extension of microglial processes
to mediate a rapid microglial response to injury (Davalos et al.,
2005) and the blockade of this receptor subtype with speciﬁc
antagonists suppresses the increase in the number of microglia
attached to myelinated axons, preventing the demyelination pro-
cess, as well as the development of tactile allodynia (Ando et al.,
2010).
CONCLUDING REMARKS
Purinergic receptors are expressed in all cell types in the CNS
and PNS, and they are involved in a complex system of cell sig-
naling. The combination of several purines, multiple types of
purinergic receptors, and ectonucleotidases open the possibility
of exerting a ﬁne regulation of neuronal and glial activities, and
of coordinating these in distinct physiological and pathological
states. While purinergic receptors have been studied extensively
in glial cells, mainly astrocytes, and microglia, our knowledge
about their inﬂuence on neuronal function and development still
remains unclear. Accordingly, it will be important to understand
how neurons respond to purines released by other neurons or glial
cells. Thus, future studies into purinergic receptor expression in
neurons and their inﬂuence on neuronal growth and excitability
will help us understand the role of neuron–glia communication in
nervous system physiology, as well as aiding the development of
therapeutic strategies adapted to speciﬁc receptors and cell types.
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